NCT00254982View on ClinicalTrials.gov

Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

593

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Psoriasis
Interventions
BIOLOGICAL

Infliximab

Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Essex Pharma GmbH

INDUSTRY

collaborator

Centocor, Inc.

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00254982 - Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED) | Biotech Hunter | Biotech Hunter